Department of Transportation proposes amendments to drug testing program
The Department of Transportation (DOT) published a notice in the Federal Register proposing to amend its drug testing program to add four opioids to its drug testing panel.
The current five-panel test used by the DOT would remain the same but the name of the opiates panel would be changed to “opioids” and would include testing for the following syntehic opioids:
- Oxymorphone; and
The DOT also proposed adding methylenedioxyamphetamine (MDA) as an initial test analyte and removing methylenedioxyethylamphetamine (MDEA) as a confirmatory test analyte.
The notice of proposed rulemaking was included in the Federal Register and included several other proposals to amend to the DOT’s current drug testing program. That notice can be found here.
According to the law firm Jackson Lewis, the proposed revision of the drug testing panel is intended to harmonize with the revised Mandatory Guidelines established by the U.S. Department of Health and Human Services (DHHS) for federal drug testing programs for urine testing, issued on Jan. 23, 2017. DHHS has set an effective date of Oct. 1, 2017, for compliance with its final revision.
Source: Jackson Lewis PC, 1/23/2017
We cannot express enough how much we have enjoyed working with BIG! It has really benefitted our processing and ease of doing business!
I enjoy collaborating with BIG, and know that if I have to reach out with a question/concern, a positive attitude with a willingness to find resolve is on the other side of an email or a phone call.
You have been the most professional and most helpful business partner that I have ever been associated with — always there to assist us and with rapid turnaround times.
I am confident whenever we add a product with your company that I will have a good experience.
We have received superior service and we know this is what you and your team strive for. We are grateful for the dedication, level of professionalism and effort shown.